
|Videos|October 23, 2017
Dr. Lebbe Discusses Efficacy of Avelumab in Merkel Cell Carcinoma
Author(s)Celeste Lebbe, MD, PhD
Celeste Lebbe, MD, PhD, Hopital Saint Louis in Paris, discusses the efficacy of avelumab (Bavencio) in patients with stage IV Merkel cell carcinoma.
Advertisement
Celeste Lebbe, MD, PhD, Hopital Saint Louis in Paris, discusses the efficacy of avelumab (Bavencio) in patients with stage IV Merkel cell carcinoma.
In a phase II study of avelumab, chemotherapy-naïve patients with distant metastatic Merkel cell carcinoma, first-line treatment resulted in early responses and a high overall response rate (ORR) in this difficult-to-treat population.
The ORR was 62%, which occurred quite rapidly, says Lebbe. The median duration of response is not yet reached, though.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5



































